Table 5 Treatment outcomes in 139 patients with abdominal tuberculosis
Characteristic | All patients (n = 139) | Luminal TB (n = 69) | Peritoneal TB (n = 28) | Nodal TB (n = 7) | Visceral TB (n = 23) | Mixed TB (n = 12) |
|---|---|---|---|---|---|---|
Duration of treatment, days | 194.0 (176.0–258.0) | 189.0 (175.0–219.0) | 200.0 (165.0–258.0) | 258.0 (16.0–285.0) | 284.0 (178.0–284.0) | 245.0 (177.5–349.0) |
Side effect | 21 (15.2%) | 11 (15.9%) | 3 (11.1%) | 0 (0%) | 4 (17.4%) | 3 (25.0%) |
Drug-induced liver injury | 9 (6.5%) | 5 (8.7%) | 2 (7.1%) | 0 (0%) | 0 (0%) | 1 (8.3%) |
Nephrectomy | 4 (2.9%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (17.4%) c, f | 0 (0%) |
First-line anti-TB drug | 131 (94.2%) | 66 (95.7%) | 27 (96.4%) | 7 (100%) | 20 (87.0%) | 11 (91.7%) |
Second-line anti-TB drug | 8 (5.8%) | 3 (4.3%) | 1 (3.6%) | 0 (0%) | 3 (13.0%) | 1 (8.3%) |
Complete response | 117 (84.2%) | 62 (89.9%) | 22 (78.6%) | 3 (42.9%) b, e, h, i | 20 (87.0%) | 10 (83.3%) |
Partial response | 1 (0.7%) | 0 (0%) | 0 (0%) | 1 (14.3%) | 0 (0%) | 0 (0%) |
No response | 2 (1.4%) | 1 (1.4%) | 0 (0%) | 0 (0%) | 1 (4.3%) | 0 (0%) |
Lost to follow up | 12 (8.6%) | 4 (5.8%) | 5 (17.9%) | 0 (0%) | 1 (4.3%) | 2 (16.7%) |
Recurrence | 3 (2.2%) | 1 (1.4%) | 1 (3.6%) | 1 (14.3%) | 0 (0%) | 0 (0%) |
Transfer out | 3 (2.2%) | 1 (1.4%) | 0 (0%) | 2 (28.6%) | 0 (0%) | 0 (0%) |
Death | 2 (1.4%) | 1 (1.4%) | 0 (0%) | 0 (0%) | 1 (4.3%) | 0 (0%) |